Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation

BackgroundThe administration of modified immune cells (MIC) before kidney transplantation led to specific immunosuppression against the allogeneic donor and a significant increase in regulatory B lymphocytes. We wondered how this approach affected the continued clinical course of these patients.Meth...

詳細記述

書誌詳細

主要な著者:	Matthias Schaier, Christian Morath, Lei Wang, Christian Kleist, Gerhard Opelz, Thuong Hien Tran, Sabine Scherer, Lien Pham, Naruemol Ekpoom, Caner Süsal, Gerald Ponath, Florian Kälble, Claudius Speer, Louise Benning, Christian Nusshag, Christoph F. Mahler, Luiza Pego da Silva, Claudia Sommerer, Angela Hückelhoven-Krauss, David Czock, Arianeb Mehrabi, Constantin Schwab, Rüdiger Waldherr, Paul Schnitzler, Uta Merle, Vedat Schwenger, Markus Krautter, Stephan Kemmner, Michael Fischereder, Manfred Stangl, Ingeborg A. Hauser, Anna-Isabelle Kälsch, Bernhard K. Krämer, Georg A. Böhmig, Carsten Müller-Tidow, Jochen Reiser, Martin Zeier, Michael Schmitt, Peter Terness, Anita Schmitt, Volker Daniel
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2023-07-01
シリーズ:	Frontiers in Immunology
主題:	transplantation - kidney tolerance cell therapy regulatory B (Breg) cells phase I (drug development)
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1089664/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!